▶ 調査レポート

キナーゼ阻害剤の世界市場:種類別(非受容体型チロシンキナーゼ阻害剤、受容体型チロシンキナーゼ阻害剤、マルチキナーゼ阻害剤、セリン/トレオニンキナーゼ阻害剤、プロテインキナーゼC阻害剤、RHOキナーゼ阻害剤、その他)、用途別(腫瘍学、炎症性疾患、その他)、流通経路別(病院薬局、独立型薬局、オンライン薬局)

• 英文タイトル:Kinase Inhibitors Market (Type: Non-receptor Tyrosine Kinase Inhibitors, Receptor Tyrosine Kinase Inhibitors, Multikinase Inhibitors, Serine/Threonine Kinase Inhibitors, Protein Kinase C Inhibitors, RHO Kinase Inhibitors, and Others; Application: Oncology, Inflammatory Diseases, and Others; and Distribution Channel: Hospital Pharmacies, Independent Pharmacies, and Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027

Transparency Market Researchが調査・発行した産業分析レポートです。キナーゼ阻害剤の世界市場:種類別(非受容体型チロシンキナーゼ阻害剤、受容体型チロシンキナーゼ阻害剤、マルチキナーゼ阻害剤、セリン/トレオニンキナーゼ阻害剤、プロテインキナーゼC阻害剤、RHOキナーゼ阻害剤、その他)、用途別(腫瘍学、炎症性疾患、その他)、流通経路別(病院薬局、独立型薬局、オンライン薬局) / Kinase Inhibitors Market (Type: Non-receptor Tyrosine Kinase Inhibitors, Receptor Tyrosine Kinase Inhibitors, Multikinase Inhibitors, Serine/Threonine Kinase Inhibitors, Protein Kinase C Inhibitors, RHO Kinase Inhibitors, and Others; Application: Oncology, Inflammatory Diseases, and Others; and Distribution Channel: Hospital Pharmacies, Independent Pharmacies, and Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027 / D0JU09089資料のイメージです。• レポートコード:D0JU09089
• 出版社/出版日:Transparency Market Research / 2020年2月10日
• レポート形態:英文、PDF、251ページ
• 納品方法:Eメール
• 産業分類:医療
• 販売価格(消費税別)
  Single User¥857,660 (USD5,795)▷ お問い合わせ
  Multi User¥1,301,660 (USD8,795)▷ お問い合わせ
  Corporate License¥1,745,660 (USD11,795)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
本調査レポートでは、キナーゼ阻害剤の世界市場について調査・分析し、序論、仮定・調査手法、エグゼクティブサマリー、市場動向、市場概要、種類別(非受容体型チロシンキナーゼ阻害剤、受容体型チロシンキナーゼ阻害剤、マルチキナーゼ阻害剤、セリン/トレオニンキナーゼ阻害剤、プロテインキナーゼC阻害剤、RHOキナーゼ阻害剤、その他)分析、用途別(腫瘍学、炎症性疾患、その他)分析、流通経路別(病院薬局、独立型薬局、オンライン薬局)分析、地域別分析、競争状況などの構成でお届けいたします。
・序論
・仮定・調査手法
・エグゼクティブサマリー
・市場動向
・市場概要
・キナーゼ阻害剤の世界市場:種類別(非受容体型チロシンキナーゼ阻害剤、受容体型チロシンキナーゼ阻害剤、マルチキナーゼ阻害剤、セリン/トレオニンキナーゼ阻害剤、プロテインキナーゼC阻害剤、RHOキナーゼ阻害剤、その他)
・キナーゼ阻害剤の世界市場:用途別(腫瘍学、炎症性疾患、その他)
・キナーゼ阻害剤の世界市場:流通経路別(病院薬局、独立型薬局、オンライン薬局)
・キナーゼ阻害剤の世界市場:地域別
・競争状況

Kinase Inhibitors Market – Scope of the Report

TMR’s report on the global kinase inhibitors market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators for the said market during the forecast period from 2019 to 2027. The report provides the overall market revenue of the global kinase inhibitors market for the period of 2017–2027, considering 2018 as the base year and 2027 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global kinase inhibitors market from 2019 to 2027.

The report has been prepared after an extensive research. Primary research involves bulk of research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Extensive secondary research involves referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the global kinase inhibitors market.

Secondary research also includes Internet sources, statistical data from government agencies, websites, and trade associations. Analysts have employed a combination of top-down and bottom-up approaches to study various attributes of the global kinase inhibitors market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments and sub-segments included in the scope of the study. Moreover, the report sheds light on changing competitive dynamics in the global kinase inhibitors market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global kinase inhibitors market.

The report delves into the competitive landscape of the global kinase inhibitors market. Key players operating in the global kinase inhibitors market have been identified and each one of them has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global kinase inhibitors market that have been profiled in this report.

Key Questions Answered in Kinase Inhibitors Market Report

What is the sales/revenue generated by the kinase inhibitors market across all regions during the forecast period?
What are the opportunities in the global kinase inhibitors market?
What are the major drivers, restraints, opportunities, and threats in the global market?
Which region is set to expand at the fastest CAGR during the forecast period?
Which product segment is expected to generate the highest revenue globally in 2027? Which segment is projected expand at the highest CAGR during the forecast period?
What are the market positions of different companies operating in the global market?
Kinase Inhibitors Market – Research Objectives and Research Approach

The comprehensive report on the global kinase inhibitors market begins with an overview, followed by the scope and objectives of the study. Following this, the report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller sections. The report comprises an exhaustive collection of graphs and tables that have been appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global kinase inhibitors market in terms of type, application, distribution channel, and region. Key segments under each criteria have been studied at length, and the market share for each of them at the end of 2027 has been provided herein. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global kinase inhibitors market.

レポート目次

1. Preface

1.1. Market Definition and Scope

1.2. Market Segmentation

1.3. Key Research Objectives

1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Kinase Inhibitors Market

4. Market Overview

4.1. Introduction & Overview

4.2. Market Dynamics

4.2.1. Drivers

4.2.2. Restraints

4.2.3. Opportunities

4.3. Porter’s Five Forces Analysis

4.4. Global Kinase Inhibitors Market Analysis and Forecast, 2017–2027

5. Market Outlook

5.1. Pipeline Analysis

5.2. Brand Analysis

5.3. Recent Developments In Kinase Inhibitors Research

6. Global Kinase Inhibitors Market Analysis and Forecasts, by Type

6.1. Introduction & Definition

6.2. Global Kinase Inhibitors Market Value (US$ Mn) Forecast, by Type, 2017–2027

6.2.1. Non-receptor Tyrosine Kinase Inhibitors

6.2.1.1. Bruton’s Tyrosine Kinase (BTK) Inhibitors

6.2.1.2. BCR-ABL

6.2.1.3. Janus Kinase (JAK) Inhibitor

6.2.1.4. Mesenchymal Epithelial Transition Growth Factor (c-MET)

6.2.1.5. Spleen Tyrosine Kinase (SYK) Inhibitors

6.2.1.6. Others

6.2.2. Receptor Tyrosine Kinase Inhibitors

6.2.2.1. VEGFR

6.2.2.2. PDGFR

6.2.2.3. EGFR

6.2.2.4. ALK

6.2.2.5. HER2

6.2.2.6. Others

6.2.3. Multikinase inhibitors

6.2.4. Serine/Threonine Kinase Inhibitors

6.2.5. Protein Kinase C Inhibitors

6.2.6. RHO Kinase Inhibitors

6.2.7. Others

6.3. Global Kinase Inhibitors Market Attractiveness, by Type

7. Global Kinase Inhibitors Market Analysis and Forecasts, by Application

7.1. Introduction & Definition

7.2. Global Kinase Inhibitors Market Value (US$) Forecast, by Application, 2017–2027

7.2.1. Oncology

7.2.1.1. Lung Cancer

7.2.1.2. Renal cell cancer

7.2.1.3. Breast Cancer

7.2.1.4. Others

7.2.2. Inflammatory Diseases

7.2.3. Others

7.3. Global Kinase Inhibitors Market Attractiveness, by Application

8. Global Kinase Inhibitors Market Analysis and Forecasts, by Distribution Channel

8.1. Introduction & Definition

8.2. Global Kinase Inhibitors Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

8.2.1. Hospital Pharmacies

8.2.2. Independent Pharmacies

8.2.3. Online Pharmacies

8.3. Global Kinase Inhibitors Market Attractiveness, by Distribution Channel

9. Global Kinase Inhibitors Market Analysis and Forecasts, by Region

9.1. Key Findings

9.2. Global Kinase Inhibitors Market Value (US$ Mn) Forecast, by Region

9.2.1. North America

9.2.2. Europe

9.2.3. Asia Pacific

9.2.4. Latin America

9.2.5. Middle East & Africa

9.3. Global Kinase Inhibitors Market Attractiveness, by Region

10. North America Kinase Inhibitors Market Analysis and Forecast

10.1. Introduction

10.2. North America Kinase Inhibitors Market Value (US$ Mn) Forecast, by Type, 2017–2027

10.2.1. Non-receptor Tyrosine Kinase Inhibitors

10.2.1.1. Bruton’s Tyrosine Kinase (BTK) Inhibitors

10.2.1.2. BCR-ABL

10.2.1.3. Janus Kinase (JAK) Inhibitor

10.2.1.4. Mesenchymal Epithelial Transition Growth Factor (c-MET)

10.2.1.5. Spleen Tyrosine Kinase (SYK) Inhibitors

10.2.1.6. Others

10.2.2. Receptor Tyrosine Kinase Inhibitors

10.2.2.1. VEGFR

10.2.2.2. PDGFR

10.2.2.3. EGFR

10.2.2.4. ALK

10.2.2.5. HER2

10.2.2.6. Others

10.2.3. Multikinase inhibitors

10.2.4. Serine/Threonine Kinase Inhibitors

10.2.5. Protein Kinase C Inhibitors

10.2.6. RHO Kinase Inhibitors

10.2.7. Others

10.3. North America Kinase Inhibitors Market Value (US$ Mn) Forecast, by Application, 2017–2027

10.3.1. Oncology

10.3.1.1. Lung Cancer

10.3.1.2. Renal cell cancer

10.3.1.3. Breast Cancer

10.3.1.4. Others

10.3.2. Inflammatory Diseases

10.3.3. Others

10.4. North America Kinase Inhibitors Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

10.4.1. Hospital Pharmacies

10.4.2. Independent Pharmacies

10.4.3. Online Pharmacies

10.5. North America Kinase Inhibitors Market Value (US$ Mn) Forecast, by Country, 2017–2027

10.5.1. U.S.

10.5.2. Canada

10.6. North America Kinase Inhibitors Market Attractiveness Analysis

10.6.1. By Type

10.6.2. By Application

10.6.3. By Distribution Channel

10.6.4. By Country

11. Europe Kinase Inhibitors Market Analysis and Forecast

11.1. Introduction

11.2. Europe Kinase Inhibitors Market Value (US$ Mn) Forecast, by Type, 2017–2027

11.2.1. Non-receptor Tyrosine Kinase Inhibitors

11.2.1.1. Bruton’s Tyrosine Kinase (BTK) Inhibitors

11.2.1.2. BCR-ABL

11.2.1.3. Janus Kinase (JAK) Inhibitor

11.2.1.4. Mesenchymal Epithelial Transition Growth Factor (c-MET)

11.2.1.5. Spleen Tyrosine Kinase (SYK) Inhibitors

11.2.1.6. Others

11.2.2. Receptor Tyrosine Kinase Inhibitors

11.2.2.1. VEGFR

11.2.2.2. PDGFR

11.2.2.3. EGFR

11.2.2.4. ALK

11.2.2.5. HER2

11.2.2.6. Others

11.2.3. Multikinase inhibitors

11.2.4. Serine/Threonine Kinase Inhibitors

11.2.5. Protein Kinase C Inhibitors

11.2.6. RHO Kinase Inhibitors

11.2.7. Others

11.3. Europe Kinase Inhibitors Market Value (US$ Mn) Forecast, by Application, 2017–2027

11.3.1. Oncology

11.3.1.1. Lung Cancer

11.3.1.2. Renal cell cancer

11.3.1.3. Breast Cancer

11.3.1.4. Others

11.3.2. Inflammatory Diseases

11.3.3. Others

11.4. Europe Kinase Inhibitors Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

11.4.1. Hospital Pharmacies

11.4.2. Independent Pharmacies

11.4.3. Online Pharmacies

11.5. Europe Kinase Inhibitors Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

11.5.1. Germany

11.5.2. U.K.

11.5.3. France

11.5.4. Spain

11.5.5. Italy

11.5.6. Rest of Europe

11.6. Europe Kinase Inhibitors Market Attractiveness Analysis

11.6.1. By Type

11.6.2. By Application

11.6.3. By Distribution Channel

11.6.4. By Country/Sub-region

12. Asia Pacific Kinase Inhibitors Market Analysis and Forecast

12.1. Introduction

12.2. Asia Pacific Kinase Inhibitors Market Value (US$ Mn) Forecast, by Type, 2017–2027

12.2.1. Non-receptor Tyrosine Kinase Inhibitors

12.2.1.1. Bruton’s Tyrosine Kinase (BTK) Inhibitors

12.2.1.2. BCR-ABL

12.2.1.3. Janus Kinase (JAK) Inhibitor

12.2.1.4. Mesenchymal Epithelial Transition Growth Factor (c-MET)

12.2.1.5. Spleen Tyrosine Kinase (SYK) Inhibitors

12.2.1.6. Others

12.2.2. Receptor Tyrosine Kinase Inhibitors

12.2.2.1. VEGFR

12.2.2.2. PDGFR

12.2.2.3. EGFR

12.2.2.4. ALK

12.2.2.5. HER2

12.2.2.6. Others

12.2.3. Multikinase inhibitors

12.2.4. Serine/Threonine Kinase Inhibitors

12.2.5. Protein Kinase C Inhibitors

12.2.6. RHO Kinase Inhibitors

12.2.7. Others

12.3. Asia Pacific Kinase Inhibitors Market Value (US$ Mn) Forecast, by Application, 2017–2027

12.3.1. Oncology

12.3.1.1. Lung Cancer

12.3.1.2. Renal cell cancer

12.3.1.3. Breast Cancer

12.3.1.4. Others

12.3.2. Inflammatory Diseases

12.3.3. Others

12.4. Asia Pacific Kinase Inhibitors Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

12.4.1. Hospital Pharmacies

12.4.2. Independent Pharmacies

12.4.3. Online Pharmacies

12.5. Asia Pacific Kinase Inhibitors Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

12.5.1. China

12.5.2. Japan

12.5.3. India

12.5.4. Australia & New Zealand

12.5.5. Rest of Asia Pacific

12.6. Asia Pacific Kinase Inhibitors Market Attractiveness Analysis

12.6.1. By Type

12.6.2. By Application

12.6.3. By Distribution Channel

12.6.4. By Country/Sub-region

13. Latin America Kinase Inhibitors Market Analysis and Forecast

13.1. Introduction

13.2. Latin America Kinase Inhibitors Market Value (US$ Mn) Forecast, by Type, 2017–2027

13.2.1. Non-receptor Tyrosine Kinase Inhibitors

13.2.1.1. Bruton’s Tyrosine Kinase (BTK) Inhibitors

13.2.1.2. BCR-ABL

13.2.1.3. Janus Kinase (JAK) Inhibitor

13.2.1.4. Mesenchymal Epithelial Transition Growth Factor (c-MET)

13.2.1.5. Spleen Tyrosine Kinase (SYK) Inhibitors

13.2.1.6. Others

13.2.2. Receptor Tyrosine Kinase Inhibitors

13.2.2.1. VEGFR

13.2.2.2. PDGFR

13.2.2.3. EGFR

13.2.2.4. ALK

13.2.2.5. HER2

13.2.2.6. Others

13.2.3. Multikinase inhibitors

13.2.4. Serine/Threonine Kinase Inhibitors

13.2.5. Protein Kinase C Inhibitors

13.2.6. RHO Kinase Inhibitors

13.2.7. Others

13.3. Latin America Kinase Inhibitors Market Value (US$ Mn) Forecast, by Application, 2017–2027

13.3.1. Oncology

13.3.1.1. Lung Cancer

13.3.1.2. Renal cell cancer

13.3.1.3. Breast Cancer

13.3.1.4. Others

13.3.2. Inflammatory Diseases

13.3.3. Others

13.4. Latin America Kinase Inhibitors Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

13.4.1. Hospital Pharmacies

13.4.2. Independent Pharmacies

13.4.3. Online Pharmacies

13.5. Latin America Kinase Inhibitors Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

13.5.1. Brazil

13.5.2. Mexico

13.5.3. Rest of Latin America

13.6. Latin America Kinase Inhibitors Market Attractiveness Analysis

13.6.1. By Type

13.6.2. By Application

13.6.3. By Distribution Channel

13.6.4. By Country/Sub-region

14. Middle East & Africa Kinase Inhibitors Market Analysis and Forecast

14.1. Introduction

14.2. Middle East & Africa Kinase Inhibitors Market Value (US$ Mn) Forecast, by Type, 2017–2027

14.2.1. Non-receptor Tyrosine Kinase Inhibitors

14.2.1.1. Bruton’s Tyrosine Kinase (BTK) Inhibitors

14.2.1.2. BCR-ABL

14.2.1.3. Janus Kinase (JAK) Inhibitor

14.2.1.4. Mesenchymal Epithelial Transition Growth Factor (c-MET)

14.2.1.5. Spleen Tyrosine Kinase (SYK) Inhibitors

14.2.1.6. Others

14.2.2. Receptor Tyrosine Kinase Inhibitors

14.2.2.1. VEGFR

14.2.2.2. PDGFR

14.2.2.3. EGFR

14.2.2.4. ALK

14.2.2.5. HER2

14.2.2.6. Others

14.2.3. Multikinase inhibitors

14.2.4. Serine/Threonine Kinase Inhibitors

14.2.5. Protein Kinase C Inhibitors

14.2.6. RHO Kinase Inhibitors

14.2.7. Others

14.3. Middle East & Africa Kinase Inhibitors Market Value (US$ Mn) Forecast, by Application, 2017–2027

14.3.1. Oncology

14.3.1.1. Lung Cancer

14.3.1.2. Renal cell cancer

14.3.1.3. Breast Cancer

14.3.1.4. Others

14.3.2. Inflammatory Diseases

14.3.3. Others

14.4. Middle East & Africa Kinase Inhibitors Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

14.4.1. Hospital Pharmacies

14.4.2. Independent Pharmacies

14.4.3. Online Pharmacies

14.5. Middle East & Africa Kinase Inhibitors Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

14.5.1. GCC Countries

14.5.2. South Africa

14.5.3. Israel

14.5.4. Rest of Middle East & Africa

14.6. Middle East & Africa Kinase Inhibitors Market Attractiveness Analysis

14.6.1. By Type

14.6.2. By Application

14.6.3. By Distribution Channel

14.6.4. By Country/Sub-region

15. Competition Landscape

15.1. Competition Matrix

15.2. Market Share Analysis, by Company (2018)

15.3. Company Profiles

15.3.1. Boehringer Ingelheim International GmbH

15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

15.3.1.2. Company Financials

15.3.1.3. Growth Strategies

15.3.1.4. SWOT Analysis

15.3.2. Novartis AG

15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

15.3.2.2. Company Financials

15.3.2.3. Growth Strategies

15.3.2.4. SWOT Analysis

15.3.3. AstraZeneca plc

15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

15.3.3.2. Company Financials

15.3.3.3. Growth Strategies

15.3.3.4. SWOT Analysis

15.3.4. Pfizer, Inc.

15.3.4.1. Company Overview (HQ, Business Segments)

15.3.4.2. Company Financials

15.3.4.3. Growth Strategies

15.3.4.4. SWOT Analysis

15.3.5. F. Hoffmann-La Roche Ltd

15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

15.3.5.2. Company Financials

15.3.5.3. Growth Strategies

15.3.5.4. SWOT Analysis

15.3.6. Bristol-Myers Squibb Company

15.3.6.1. Company Overview (HQ, Business Segments)

15.3.6.2. Company Financials

15.3.6.3. Growth Strategies

15.3.6.4. SWOT Analysis

15.3.7. Johnson & Johnson

15.3.7.1. Company Overview (HQ, Business Segments)

15.3.7.2. Company Financials

15.3.7.3. Growth Strategies

15.3.7.4. SWOT Analysis

15.3.8. Bayer AG

15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

15.3.8.2. Company Financials

15.3.8.3. Growth Strategies

15.3.8.4. SWOT Analysis

15.3.9. Eisai Co., Ltd.

15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

15.3.9.2. Company Financials

15.3.9.3. Growth Strategies

15.3.9.4. SWOT Analysis

List of Tables

Table 01: Global BCR-ABL Tyrosine Kinase Inhibitors Market Revenue (US$ Mn) Forecast, by Key Brands, 2016-2026

Table 02: Global EGFR Tyrosine Kinase Inhibitors Market Revenue (US$ Mn) Forecast, by Key Brands, 2016-2026

Table 03: Global VEGFR Tyrosine Kinase Inhibitors Market Revenue (US$ Mn) Forecast, by Key Brands, 2016-2026

Table 04: Global Other Tyrosine Kinase Inhibitors Market Revenue (US$ Mn) Forecast, by Key Brands, 2016-2026

Table 05: Patent & Market Exclusivity Overview, by Molecule (1/4)

Table 06: Patent & Market Exclusivity Overview, by Molecule (2/4)

Table 07: Patent & Market Exclusivity Overview, by Molecule (3/4)

Table 08: Patent & Market Exclusivity Overview, by Molecule (4/4)

Table 09: Global Kinase Inhibitors Market Value (US$ Mn) Forecast, by Type, 2017–2027

Table 10: Global Kinase Inhibitors Market Value (US$ Mn) Forecast, by Non-receptor Tyrosine Kinase Inhibitors, 2017–2027

Table 11: Global Kinase Inhibitors Market Value (US$ Mn) Forecast, by Receptor Tyrosine Kinase Inhibitors, 2017–2027

Table 12: Global Kinase Inhibitors Market Value (US$ Mn) Forecast, by Application, 2017–2027

Table 13: Global Kinase Inhibitors Market Value (US$ Mn) Forecast, by Oncology, 2017–2027

Table 14: Global Kinase Inhibitors Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 15: Global Kinase Inhibitors Market Value (US$ Mn) Forecast, by Region, 2017–2027

Table 16: North America Kinase Inhibitors Market Value (US$ Mn) Forecast, by Type, 2017–2027

Table 17: North America Kinase Inhibitors Market Value (US$ Mn) Forecast, by Non-receptor Tyrosine Kinase Inhibitors, 2017–2027

Table 18: North America Kinase Inhibitors Market Value (US$ Mn) Forecast, by Receptor Tyrosine Kinase Inhibitors, 2017–2027

Table 19: North America Kinase Inhibitors Market Value (US$ Mn) Forecast, by Application, 2017–2027

Table 20: North America Kinase Inhibitors Market Value (US$ Mn) Forecast, by Oncology, 2017–2027

Table 21: North America Kinase Inhibitors Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 22: North America Kinase Inhibitors Market Value (US$ Mn) Forecast, by Country, 2017–2027

Table 23: Europe Kinase Inhibitors Market Value (US$ Mn) Forecast, by Type, 2017–2027

Table 24: Europe Kinase Inhibitors Market Value (US$ Mn) Forecast, by Non-receptor Tyrosine Kinase Inhibitors, 2017–2027

Table 25: Europe Kinase Inhibitors Market Value (US$ Mn) Forecast, by Receptor Tyrosine Kinase Inhibitors, 2017–2027

Table 26: Europe Kinase Inhibitors Market Value (US$ Mn) Forecast, by Application, 2017–2027

Table 27: Europe Kinase Inhibitors Market Value (US$ Mn) Forecast, by Oncology, 2017–2027

Table 28: Europe Kinase Inhibitors Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 29: Europe Kinase Inhibitors Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

Table 30: Asia Pacific Kinase Inhibitors Market Value (US$ Mn) Forecast, by Type, 2017–2027

Table 31: Asia Pacific Kinase Inhibitors Market Value (US$ Mn) Forecast, by Non-receptor Tyrosine Kinase Inhibitors, 2017–2027

Table 32: Asia Pacific Kinase Inhibitors Market Value (US$ Mn) Forecast, by Receptor Tyrosine Kinase Inhibitors, 2017–2027

Table 33: Asia Pacific Kinase Inhibitors Market Value (US$ Mn) Forecast, by Application, 2017–2027

Table 34: Asia Pacific Kinase Inhibitors Market Value (US$ Mn) Forecast, by Oncology, 2017–2027

Table 35: Asia Pacific Kinase Inhibitors Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 36: Asia Pacific Kinase Inhibitors Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

Table 37: Latin America Kinase Inhibitors Market Value (US$ Mn) Forecast, by Type, 2017–2027

Table 38: Latin America Kinase Inhibitors Market Value (US$ Mn) Forecast, by Non-receptor Tyrosine Kinase Inhibitors, 2017–2027

Table 39: Latin America Kinase Inhibitors Market Value (US$ Mn) Forecast, by Receptor Tyrosine Kinase Inhibitors, 2017–2027

Table 40: Latin America Kinase Inhibitors Market Value (US$ Mn) Forecast, by Application, 2017–2027

Table 41: Latin America Kinase Inhibitors Market Value (US$ Mn) Forecast, by Oncology, 2017–2027

Table 42: Latin America Kinase Inhibitors Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 43: Latin America Kinase Inhibitors Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

Table 44: Middle East & Africa Kinase Inhibitors Market Value (US$ Mn) Forecast, by Type, 2017–2027

Table 45: Middle East & Africa Kinase Inhibitors Market Value (US$ Mn) Forecast, by Non-receptor Tyrosine Kinase Inhibitors, 2017–2027

Table 46: Middle East & Africa Kinase Inhibitors Market Value (US$ Mn) Forecast, by Receptor Tyrosine Kinase Inhibitors, 2017–2027

Table 47: Middle East & Africa Kinase Inhibitors Market Value (US$ Mn) Forecast, by Application, 2017–2027

Table 48: Middle East & Africa Kinase Inhibitors Market Value (US$ Mn) Forecast, by Oncology, 2017–2027

Table 49: Middle East & Africa Kinase Inhibitors Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 50: Middle East & Africa Kinase Inhibitors Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027